• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis.冠心病患者出血与心肌梗死的死亡率:系统评价和荟萃分析。
EuroIntervention. 2021 Sep 20;17(7):550-560. doi: 10.4244/EIJ-D-20-01197.
2
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention.出血和心肌梗死对接受经皮冠状动脉介入治疗的所有患者死亡率的影响。
Circ Cardiovasc Interv. 2020 Sep;13(9):e009177. doi: 10.1161/CIRCINTERVENTIONS.120.009177. Epub 2020 Aug 25.
3
Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.替格瑞洛与冠心病常规抗血小板药物比较:15 项随机试验的综合荟萃分析。
Vascul Pharmacol. 2021 Apr;137:106828. doi: 10.1016/j.vph.2020.106828. Epub 2020 Dec 29.
4
Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.经皮冠状动脉介入治疗对稳定型和不稳定型冠状动脉疾病分层的死亡和心肌梗死的影响:一项随机对照试验的荟萃分析
Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e006363. doi: 10.1161/CIRCOUTCOMES.119.006363. Epub 2020 Feb 17.
5
Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes.急性冠状动脉综合征患者经皮冠状动脉介入治疗后出血、心肌梗死和死亡风险预测。
Coron Artery Dis. 2022 May 1;33(3):213-221. doi: 10.1097/MCA.0000000000001120.
6
Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.双联或三联抗栓治疗患者的出血和缺血结局:系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):226-236. doi: 10.1093/ehjcvp/pvz021.
7
Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy).吸烟对非 ST 段抬高急性冠状动脉综合征患者冠状动脉疾病程度和预后的影响:来自 ACUITY 试验(急性血管成形术和紧急介入治疗策略)的分析。
JACC Cardiovasc Interv. 2014 Apr;7(4):372-9. doi: 10.1016/j.jcin.2013.11.017. Epub 2014 Mar 14.
8
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.氯吡格雷预处理与经皮冠状动脉介入治疗患者的死亡率、心血管事件和主要出血的关系:系统评价和荟萃分析。
JAMA. 2012 Dec 19;308(23):2507-16. doi: 10.1001/jama.2012.50788.
9
Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.急性冠状动脉综合征经皮冠状动脉介入治疗患者中 3 个月与 12 个月双联抗血小板治疗时长的比较:一项随机对照试验的荟萃分析。
Catheter Cardiovasc Interv. 2022 Dec;100(7):1151-1158. doi: 10.1002/ccd.30467. Epub 2022 Nov 3.
10
Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial.心梗病史与替格瑞洛和普拉格雷在急性冠脉综合征患者中的治疗效果 - ISAR-REACT 5 试验的事后分析。
J Am Heart Assoc. 2022 Dec 20;11(24):e027257. doi: 10.1161/JAHA.122.027257. Epub 2022 Dec 14.

引用本文的文献

1
Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis.冠心病患者抗血栓治疗疗效与安全性的性别差异:系统评价与荟萃分析
BMJ. 2025 Jul 29;390:e082974. doi: 10.1136/bmj-2024-082974.
2
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.在高出血风险糖尿病患者中,依维莫司洗脱支架植入术后1个月与3个月双重抗血小板治疗对比:XIENCE短期双重抗血小板治疗项目结果
EuroIntervention. 2025 Jun 16;21(12):e668-e680. doi: 10.4244/EIJ-D-24-00897.
3
Procedural and Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Narrative Review.接受经皮冠状动脉介入治疗的心房颤动患者的手术及抗栓治疗优化:一篇叙述性综述
J Cardiovasc Dev Dis. 2025 Apr 8;12(4):142. doi: 10.3390/jcdd12040142.
4
Impact of Mild Hypothermia As Adjunctive Therapy in Patients With ST-Elevation Myocardial Infarction: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.轻度低温作为ST段抬高型心肌梗死患者辅助治疗的影响:一项随机对照试验的荟萃分析和试验序贯分析
Catheter Cardiovasc Interv. 2025 Feb;105(3):543-556. doi: 10.1002/ccd.31351. Epub 2024 Dec 15.
5
Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.急性冠状动脉综合征行经皮冠状动脉介入治疗患者的抗血小板策略:系统评价和网络荟萃分析。
J Am Heart Assoc. 2024 Oct 15;13(20):e032490. doi: 10.1161/JAHA.122.032490. Epub 2024 Oct 11.
6
Unraveling the Complexities for Antiplatelet Strategies Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.解析接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者抗血小板策略的复杂性
J Am Heart Assoc. 2024 Oct 15;13(20):e037643. doi: 10.1161/JAHA.124.037643. Epub 2024 Oct 11.
7
P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI.P2Y12抑制剂单药治疗:PCI术后急性和长期二级预防的考量
Rev Cardiovasc Med. 2022 Oct 17;23(10):348. doi: 10.31083/j.rcm2310348. eCollection 2022 Oct.
8
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗患者的出血并发症
Rev Cardiovasc Med. 2022 Aug 15;23(8):286. doi: 10.31083/j.rcm2308286. eCollection 2022 Aug.
9
Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.老年急性冠状动脉综合征患者行经皮冠状动脉介入治疗时的抗血小板治疗
J Clin Med. 2024 Jul 19;13(14):4229. doi: 10.3390/jcm13144229.
10
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.非ST段抬高型急性冠状动脉综合征患者接受经皮冠状动脉介入治疗时,高出血风险患者的1个月与3个月双重抗血小板治疗对比研究
EuroIntervention. 2024 May 20;20(10):e630-e642. doi: 10.4244/EIJ-D-23-00658.

本文引用的文献

1
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention.出血和心肌梗死对接受经皮冠状动脉介入治疗的所有患者死亡率的影响。
Circ Cardiovasc Interv. 2020 Sep;13(9):e009177. doi: 10.1161/CIRCINTERVENTIONS.120.009177. Epub 2020 Aug 25.
2
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.心房颤动合并稳定性冠心病的抗栓治疗。
N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.
3
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.定义行经皮冠状动脉介入治疗患者的高出血风险。
Circulation. 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22.
4
Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients.当代急性冠状动脉综合征患者中,心肌梗死与出血严重程度对死亡率的预后影响差异
Rev Esp Cardiol (Engl Ed). 2018 Oct;71(10):829-836. doi: 10.1016/j.rec.2018.02.008. Epub 2018 Apr 12.
5
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.氯吡格雷治疗对心血管和脑血管疾病患者死亡率和癌症的影响:一项基于患者水平的荟萃分析。
Circ Cardiovasc Interv. 2018 Jan;11(1):e005795. doi: 10.1161/CIRCINTERVENTIONS.117.005795.
6
Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting.与冠状动脉支架置入术后双联抗血小板治疗时间相关的出血相关死亡。
J Am Coll Cardiol. 2017 Apr 25;69(16):2011-2022. doi: 10.1016/j.jacc.2017.02.029.
7
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.急性冠状动脉综合征后心肌梗死与出血类型对死亡率的权衡:来自急性冠状动脉综合征临床事件减少凝血酶受体拮抗剂(TRACER)随机试验的经验教训。
Eur Heart J. 2017 Mar 14;38(11):804-810. doi: 10.1093/eurheartj/ehw525.
8
2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.聚合物涂层药物洗脱支架置入后高出血风险患者的 2 年结局
J Am Coll Cardiol. 2017 Jan 17;69(2):162-171. doi: 10.1016/j.jacc.2016.10.009. Epub 2016 Oct 30.
9
Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.经皮冠状动脉介入治疗后出血、冠状动脉血栓事件与死亡率的时间相关性:PARIS 注册研究结果。
JACC Cardiovasc Interv. 2016 Jul 11;9(13):1349-57. doi: 10.1016/j.jcin.2016.04.009.
10
Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies.与男性相比,心房颤动作为女性心血管疾病和死亡的风险因素:队列研究的系统评价和荟萃分析
BMJ. 2016 Jan 19;532:h7013. doi: 10.1136/bmj.h7013.

冠心病患者出血与心肌梗死的死亡率:系统评价和荟萃分析。

Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis.

机构信息

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

出版信息

EuroIntervention. 2021 Sep 20;17(7):550-560. doi: 10.4244/EIJ-D-20-01197.

DOI:10.4244/EIJ-D-20-01197
PMID:33840639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9725060/
Abstract

BACKGROUND

Bleeding is the principal safety concern of antithrombotic therapy and occurs frequently among patients with coronary artery disease (CAD).

AIMS

We aimed to evaluate the prognostic impact of bleeding on mortality compared with that of myocardial infarction (MI) in patients with CAD.

METHODS

We searched Medline and Embase for studies that included patients with CAD and that reported both the association between the occurrence of bleeding and mortality, and between the occurrence of MI and mortality within the same population. Adjusted hazard ratios (HRs) for mortality associated with bleeding and MI were extracted and ratios of hazard ratios (rHRs) were pooled by using inverse variance weighted random effects meta-analyses. Early events included periprocedural or within 30-day events after revascularisation or acute coronary syndrome (ACS). Late events included spontaneous or beyond 30-day events after revascularisation or ACS.

RESULTS

A total of 141,059 patients were included across 16 studies; 128,660 (91%) underwent percutaneous coronary intervention. Major bleeding increased the risk of mortality to the same extent as MI (rHRsbleedingvsMI 1.10, 95% CI: 0.71-1.71, p=0.668). Early bleeding was associated with a higher risk of mortality than early MI (rHRsbleedingvsMI 1.46, 95% CI: 1.13-1.89, p=0.004), although this finding was not present when only randomised trials were included. Late bleeding was prognostically comparable to late MI (rHRsbleedingvsMI 1.14, 95% CI: 0.87-1.49, p=0.358).

CONCLUSIONS

Compared with MI, major and late bleeding is associated with a similar increase in mortality, whereas early bleeding might have a stronger association with mortality.

摘要

背景

出血是抗血栓治疗的主要安全关注点,在患有冠状动脉疾病(CAD)的患者中经常发生。

目的

我们旨在评估与 CAD 患者的死亡率相比,出血对死亡率的预后影响。

方法

我们在 Medline 和 Embase 上搜索了包括 CAD 患者在内的研究,并报告了出血与死亡率之间以及心肌梗死(MI)与死亡率之间在同一人群中的关联。提取与出血和 MI 相关的死亡率的调整风险比(HR),并通过使用逆方差加权随机效应荟萃分析对风险比的比值(rHR)进行汇总。早期事件包括血管重建或急性冠状动脉综合征(ACS)后的围手术期或 30 天内事件。晚期事件包括血管重建或 ACS 后自发性或超过 30 天的事件。

结果

共有 16 项研究纳入了 141059 例患者;其中 128660 例(91%)接受了经皮冠状动脉介入治疗。大出血增加了死亡率的风险,与 MI 相同(rHRsbleedingvsMI 1.10,95%CI:0.71-1.71,p=0.668)。早期出血与死亡率的相关性高于早期 MI(rHRsbleedingvsMI 1.46,95%CI:1.13-1.89,p=0.004),但仅纳入随机试验时则没有这种发现。晚期出血与晚期 MI 的预后相似(rHRsbleedingvsMI 1.14,95%CI:0.87-1.49,p=0.358)。

结论

与 MI 相比,大出血和晚期出血与死亡率的增加相关,而早期出血可能与死亡率的相关性更强。